(-0.98%) 5 065.92 points
(-1.11%) 37 959 points
(-1.18%) 15 794 points
(-1.09%) $81.73
(-2.27%) $1.984
(-2.33%) $2 302.70
(-3.74%) $26.63
(-1.71%) $945.10
(0.42%) $0.936
(0.95%) $11.09
(0.45%) $0.800
(0.14%) $93.43
0.53% ¥ 1 514.00
Live Chart Being Loaded With Signals
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant...
Stats | |
---|---|
Tagesvolumen | 10.25M |
Durchschnittsvolumen | 9.29M |
Marktkapitalisierung | 2 714.75B |
EPS | ¥0 ( 2024-04-25 ) |
Last Dividend | ¥30.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 558.67 |
ATR14 | ¥0.662 (0.04%) |
Volumen Korrelation
Astellas Pharma Inc. Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Astellas Pharma Inc. Korrelation - Währung/Rohstoff
Astellas Pharma Inc. Finanzdaten
Annual | 2023 |
Umsatz: | ¥1 603.67B |
Bruttogewinn: | ¥1 212.37B (75.60 %) |
EPS: | ¥9.50 |
FY | 2023 |
Umsatz: | ¥1 603.67B |
Bruttogewinn: | ¥1 212.37B (75.60 %) |
EPS: | ¥9.50 |
FY | 2022 |
Umsatz: | ¥1 518.62B |
Bruttogewinn: | ¥1 230.27B (81.01 %) |
EPS: | ¥54.24 |
FY | 2022 |
Umsatz: | ¥1 296.16B |
Bruttogewinn: | ¥1 043.15B (80.48 %) |
EPS: | ¥67.08 |
Financial Reports:
No articles found.
Astellas Pharma Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥30.00 (N/A) |
¥0 (N/A) |
¥30.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥3.00 | 2000-03-28 |
Last Dividend | ¥30.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | ¥591.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.71 | -- |
Div. Sustainability Score | 8.06 | |
Div.Growth Potential Score | 6.81 | |
Div. Directional Score | 7.43 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8060.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
7326.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6571.T | Ex Dividend Junior | 2024-06-27 | Sporadic | 0 | 0.00% | |
5929.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4595.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3836.T | Ex Dividend Knight | 2024-06-27 | Annually | 0 | 0.00% | |
3087.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
1954.T | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
9960.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8960.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00805 | 1.500 | 9.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00362 | 1.200 | 9.88 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00817 | 1.500 | -1.020 | -1.530 | [0.1 - 1] |
payoutRatioTTM | 9.04 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.929 | 0.800 | -0.354 | -0.283 | [1 - 3] |
quickRatioTTM | 0.687 | 0.800 | -0.663 | -0.530 | [0.8 - 2.5] |
cashRatioTTM | 0.261 | 1.500 | 9.66 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.258 | -1.500 | 5.70 | -8.56 | [0 - 0.6] |
interestCoverageTTM | 8.97 | 1.000 | 7.79 | 7.79 | [3 - 30] |
operatingCashFlowPerShareTTM | 97.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 51.61 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.576 | -1.500 | 7.69 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.797 | 1.000 | 0.0457 | 0.0457 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0672 | 1.000 | -0.657 | -0.657 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.190 | 1.000 | -0.0541 | -0.0541 | [0.2 - 2] |
assetTurnoverTTM | 0.449 | 0.800 | -0.338 | -0.271 | [0.5 - 2] |
Total Score | 8.06 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 210.39 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00817 | 2.50 | -0.656 | -1.530 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 51.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.62 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 97.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 9.04 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 63.54 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.109 | 1.000 | 9.77 | 0 | [0.1 - 0.5] |
Total Score | 6.81 |
Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.